SI2277890T1 - Peptid, sposoben podaljšanja razpolovne dobe peptida, ki je zanimiv, v plazmi - Google Patents
Peptid, sposoben podaljšanja razpolovne dobe peptida, ki je zanimiv, v plazmiInfo
- Publication number
- SI2277890T1 SI2277890T1 SI200931387T SI200931387T SI2277890T1 SI 2277890 T1 SI2277890 T1 SI 2277890T1 SI 200931387 T SI200931387 T SI 200931387T SI 200931387 T SI200931387 T SI 200931387T SI 2277890 T1 SI2277890 T1 SI 2277890T1
- Authority
- SI
- Slovenia
- Prior art keywords
- peptide
- interest
- plasma
- life
- extending half
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/63—Motilins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008136106 | 2008-05-23 | ||
PCT/JP2009/059464 WO2009142307A1 (ja) | 2008-05-23 | 2009-05-22 | 目的ペプチドの血漿中半減期延長作用を有するペプチド |
EP09750669.5A EP2277890B1 (en) | 2008-05-23 | 2009-05-22 | Peptide capable of extending half-life of peptide of interest in plasma |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2277890T1 true SI2277890T1 (sl) | 2016-04-29 |
Family
ID=41340233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200931387T SI2277890T1 (sl) | 2008-05-23 | 2009-05-22 | Peptid, sposoben podaljšanja razpolovne dobe peptida, ki je zanimiv, v plazmi |
Country Status (16)
Country | Link |
---|---|
US (1) | US8551937B2 (sl) |
EP (1) | EP2277890B1 (sl) |
JP (1) | JP5524049B2 (sl) |
KR (2) | KR101350251B1 (sl) |
CN (1) | CN101809029B (sl) |
BR (1) | BRPI0904622A2 (sl) |
CA (1) | CA2698582C (sl) |
CY (1) | CY1117478T1 (sl) |
DK (1) | DK2277890T3 (sl) |
ES (1) | ES2566830T3 (sl) |
HR (1) | HRP20160303T1 (sl) |
HU (1) | HUE028539T2 (sl) |
PL (1) | PL2277890T3 (sl) |
PT (1) | PT2277890E (sl) |
SI (1) | SI2277890T1 (sl) |
WO (1) | WO2009142307A1 (sl) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3404102T3 (da) | 2004-04-21 | 2021-09-06 | Alexion Pharma Inc | Knogletilførselskonjugater og fremgangsmåde til anvendelse heraf til målretning af proteiner mod knogle |
EP3175863B1 (en) | 2009-05-20 | 2021-12-01 | BioMarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
US9266939B2 (en) | 2010-12-27 | 2016-02-23 | Alexion Pharmaceuticals, Inc. | Compositions comprising natriuretic peptides and methods of use thereof |
EP2481751A1 (en) * | 2011-01-26 | 2012-08-01 | PharmaSurgics in Sweden AB | Human lactoferrin derived peptides |
EP3189835B1 (en) | 2011-02-28 | 2018-07-25 | National Cerebral and Cardiovascular Center | Medical agent for suppressing malignant tumor metastasis |
KR20140054084A (ko) | 2011-08-19 | 2014-05-08 | 도쿠리츠교세이호진 고쿠리츠쥰칸키뵤 겐큐센터 | 나트륨 이뇨 펩티드 수용체 gc-a 아고니스트 및 gc-b 아고니스트를 조합하여 이루어지는 악성 종양의 악화 방지용 의약 |
JPWO2013099376A1 (ja) * | 2011-12-26 | 2015-04-30 | 国立大学法人福井大学 | 体外受精における成熟卵子マーカー及びその使用 |
JPWO2013161895A1 (ja) * | 2012-04-25 | 2015-12-24 | 第一三共株式会社 | 骨修復促進剤 |
MX349035B (es) | 2012-05-17 | 2017-07-07 | Extend Biosciences Inc | Portadores para el suministro mejorado de farmaco. |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
TW201442721A (zh) | 2013-01-23 | 2014-11-16 | Daiichi Sankyo Co Ltd | 糖鏈修飾心房利尿鈉肽 |
CN106232141A (zh) * | 2014-02-27 | 2016-12-14 | 第三共株式会社 | 针对由给予类固醇诱发的生长不足的药物 |
US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
JP6946182B2 (ja) | 2014-10-22 | 2021-10-06 | エクステンド バイオサイエンシズ インコーポレーテッドExtend Biosciences, Inc | 治療用ビタミンdコンジュゲート |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
JP6787894B2 (ja) | 2014-12-05 | 2020-11-18 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 組換えアルカリホスファターゼを用いた発作の処置 |
CA2973883A1 (en) | 2015-01-28 | 2016-08-04 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
CN108350440A (zh) | 2015-08-17 | 2018-07-31 | 阿雷克森制药公司 | 碱性磷酸酯的制造 |
EP3355904A4 (en) | 2015-09-28 | 2019-06-12 | Alexion Pharmaceuticals, Inc. | IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA |
WO2017074466A1 (en) | 2015-10-30 | 2017-05-04 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
EP4162955A1 (en) * | 2016-01-08 | 2023-04-12 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
US11065306B2 (en) | 2016-03-08 | 2021-07-20 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
MX2018011833A (es) | 2016-04-01 | 2019-02-13 | Alexion Pharma Inc | Tratamiento para la debilidad muscular con fosfatasas alcalinas. |
US10898549B2 (en) | 2016-04-01 | 2021-01-26 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
MX2018013546A (es) * | 2016-05-06 | 2019-04-22 | Phasebio Pharmaceuticals Inc | Proteinas de fusion de elp para liberacion controlada y sostenida. |
WO2017214130A1 (en) | 2016-06-06 | 2017-12-14 | Alexion Pharmaceuticals, Inc. | Metal impact on manufacturing of alkaline phosphatases |
EP3500289A4 (en) | 2016-08-18 | 2020-05-06 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATING TRACHEOBRONCHOMALACIA |
WO2018139464A1 (ja) | 2017-01-24 | 2018-08-02 | 第一三共株式会社 | 低身長症治療剤 |
EP3601314A4 (en) * | 2017-03-22 | 2021-01-13 | Pharmain Corporation | NPRA AGONISTS, COMPOSITIONS AND CORRESPONDING USES |
CA3057502A1 (en) | 2017-03-31 | 2018-10-04 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia (hpp) in adults and adolescents |
JP2021519590A (ja) | 2018-03-30 | 2021-08-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 糖タンパク質の製造 |
WO2020138948A2 (ko) * | 2018-12-26 | 2020-07-02 | 아미코젠주식회사 | 아세틸콜린 수용체 저해 펩타이드 및 이의 용도 |
BR112021024938A2 (pt) | 2019-06-12 | 2022-01-25 | Novartis Ag | Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3026354B2 (ja) * | 1990-09-27 | 2000-03-27 | 壽之 松尾 | ヒトcnp遺伝子及び前駆体蛋白 |
US20060263382A1 (en) * | 1998-06-20 | 2006-11-23 | Richard Hotchkiss | Membrane-permeant peptide complexes for treatment of sepsis |
ATE366813T1 (de) | 1999-07-23 | 2007-08-15 | Kenji Kangawa | Neue peptide |
CN101177455A (zh) * | 2001-08-30 | 2008-05-14 | 比奥雷克西斯药物公司 | 经修饰的运铁蛋白融合蛋白 |
BR0212256A (pt) * | 2001-08-30 | 2004-08-31 | Biorexis Pharmaceutical Corp | Proteìnas de fusão de transferrina modificadas |
US20090305969A1 (en) | 2005-11-21 | 2009-12-10 | Noboru Murakami | Skin Repair Accelerating Therapeutic Agent Containing Desacyl Ghrelin and Derivatives Thereof as Active Ingredient |
KR20080075530A (ko) | 2005-11-21 | 2008-08-18 | 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 | 그렐린, 그 유도체 또는 GHS-R1a에 작용하는 물질을유효 성분으로 포함하는 피부 수복 촉진 치료제 |
BRPI0715809A2 (pt) * | 2006-08-11 | 2014-11-25 | Univ Miyazaki | Agente terapêutico para a aceleração da restauração do nervo espinhal compreendendo grelina, seus derivados ou substâncias capazes de atuar sobre o ghs-r1a como ingrediente ativo. |
WO2008018597A1 (fr) * | 2006-08-11 | 2008-02-14 | University Of Miyazaki | Agent thérapeutique permettant d'accélérer la réparation des nerfs rachidiens comprenant en tant que matière active de la désacyl ghréline ou un dérivé de celle-ci |
US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
-
2009
- 2009-05-22 SI SI200931387T patent/SI2277890T1/sl unknown
- 2009-05-22 PT PT97506695T patent/PT2277890E/pt unknown
- 2009-05-22 CA CA2698582A patent/CA2698582C/en not_active Expired - Fee Related
- 2009-05-22 KR KR1020107004795A patent/KR101350251B1/ko active IP Right Grant
- 2009-05-22 WO PCT/JP2009/059464 patent/WO2009142307A1/ja active Application Filing
- 2009-05-22 BR BRPI0904622A patent/BRPI0904622A2/pt not_active Application Discontinuation
- 2009-05-22 HU HUE09750669A patent/HUE028539T2/en unknown
- 2009-05-22 PL PL09750669T patent/PL2277890T3/pl unknown
- 2009-05-22 CN CN200980100291.9A patent/CN101809029B/zh not_active Expired - Fee Related
- 2009-05-22 JP JP2010513074A patent/JP5524049B2/ja not_active Expired - Fee Related
- 2009-05-22 DK DK09750669.5T patent/DK2277890T3/en active
- 2009-05-22 US US12/675,961 patent/US8551937B2/en active Active
- 2009-05-22 KR KR1020127034358A patent/KR20130018965A/ko not_active Application Discontinuation
- 2009-05-22 ES ES09750669.5T patent/ES2566830T3/es active Active
- 2009-05-22 EP EP09750669.5A patent/EP2277890B1/en active Active
-
2016
- 2016-03-22 CY CY20161100242T patent/CY1117478T1/el unknown
- 2016-03-23 HR HRP20160303TT patent/HRP20160303T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
JP5524049B2 (ja) | 2014-06-18 |
US8551937B2 (en) | 2013-10-08 |
HUE028539T2 (en) | 2016-12-28 |
KR20100038236A (ko) | 2010-04-13 |
BRPI0904622A2 (pt) | 2016-06-21 |
DK2277890T3 (en) | 2016-02-08 |
KR20130018965A (ko) | 2013-02-25 |
PT2277890E (pt) | 2016-03-31 |
JPWO2009142307A1 (ja) | 2011-09-29 |
EP2277890B1 (en) | 2016-01-06 |
PL2277890T3 (pl) | 2016-06-30 |
CN101809029B (zh) | 2016-06-15 |
CY1117478T1 (el) | 2017-04-26 |
KR101350251B1 (ko) | 2014-01-14 |
CA2698582A1 (en) | 2009-11-26 |
HRP20160303T1 (hr) | 2016-04-22 |
WO2009142307A1 (ja) | 2009-11-26 |
CN101809029A (zh) | 2010-08-18 |
CA2698582C (en) | 2016-09-13 |
EP2277890A4 (en) | 2011-08-24 |
EP2277890A1 (en) | 2011-01-26 |
ES2566830T3 (es) | 2016-04-15 |
US20100305031A1 (en) | 2010-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2277890T3 (pl) | Peptyd zdolny do wydłużenia czasu półtrwania w osoczu peptydu będącego przedmiotem zainteresowania | |
HK1250042A1 (zh) | 溶酶體靶向肽及其應用 | |
EP2373679A4 (en) | HEPPIDINE MINI PEPTIDES AND METHODS OF USE | |
GB0914110D0 (en) | Peptide libraries | |
GB0913775D0 (en) | Multispecific peptides | |
EP2249853A4 (en) | PEPTIDE PRODRUGS BASED ON ESTERS | |
HK1214177A1 (zh) | 用於癌症的肽治療劑 | |
EP2131390A4 (en) | PLASMA PROCESSOR | |
EP2346521A4 (en) | PEPTIDES AND METHODS OF USE | |
PL2421884T3 (pl) | Aktywatory proteasomowe w formie hydrolizatu peptydowego i zawierające je kompozycje | |
IL216223A0 (en) | Methods of analyzing peptide mixtures | |
GB0920981D0 (en) | Peptides | |
EP2373272A4 (en) | STALL ARTICLE | |
TWI319863B (en) | Plasma display | |
EP2270141A4 (en) | Lacritin PART PEPTIDE | |
HK1217912A1 (zh) | 控釋肽製劑 | |
EP2123666A4 (en) | PEPTIDE | |
EP2478010A4 (en) | PART PEPTIDE OF LACRITINE | |
IL216199A (en) | A peptide containing the sequence ednimvtfrnqasr | |
EP2285827A4 (en) | PEPTIDES AND ITS USE | |
GB0724953D0 (en) | Methods of peptide modification | |
HK1151242A1 (en) | Mntf peptide compositions and methods of use mntf | |
ZA201203722B (en) | Peptide | |
EP2504065A4 (en) | STABLE MIXTURES AND RELATED METHODS | |
EP2188305A4 (en) | MODIFIED PEPTIDES HAVING TOXIN IMPROVING EFFECTS |